Beximco Sees Profit Jump By A Sixth
Double-Digit Domestic And Export Growth Powers Performance
Bangladesh’s biggest pharmaceutical company, Beximco Pharmaceuticals, has posted a 16.7% jump in after-tax profit in its financial first half, powered by double-digit domestic and export revenue growth.
You may also be interested in...
Bangladeshi generics manufacturer Beximco has reported 12.3% annual sales growth for its 2020 financial year and 9.9% turnover growth for its financial first quarter ending 30 September 2020. The company remains focused on expanding its portfolio and consolidating its international presence.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.
Beximco has bolstered its position in the US by bumping up its portfolio to 14 approved generics through a deal with Sandoz for a portfolio of eight ANDAs.